EUVIMEDEUVIMED entdecken
Crossref

Lecanemab Gains FDA Approval for Early Alzheimer Disease

Howard D Larkin

JAMA · 2023

DOI: 10.1001/jama.2022.24490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, 2023. Verfasst von Howard D Larkin. Hauptthemen laut MEDLINE: Alzheimer Disease, Drug Approval, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 48-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDrug ApprovalAntibodies, Monoclonal, HumanizedHumansUnited StatesUnited States Food and Drug Administration

Substanzen

lecanemabAntibodies, Monoclonal, Humanized

Zitieren

APA

Larkin, H. D. (2023). Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA. https://doi.org/10.1001/jama.2022.24490

Vancouver

Larkin HD. Lecanemab Gains FDA Approval for Early Alzheimer Disease. JAMA. 2023. doi:10.1001/jama.2022.24490

BibTeX
@article{Larkin2023,
  author = {Larkin, Howard D},
  title = {Lecanemab Gains FDA Approval for Early Alzheimer Disease},
  journal = {JAMA},
  year = {2023},
  doi = {10.1001/jama.2022.24490}
}
Kostenlos starten →